Click to Translate to English Click to Translate to French  Click to Translate to Spanish  Click to Translate to German  Click to Translate to Italian  Click to Translate to Japanese  Click to Translate to Chinese Simplified  Click to Translate to Korean  Click to Translate to Arabic  Click to Translate to Russian  Click to Translate to Portuguese


Forum Home Forum Home > General Discussion > Latest News
  New Posts New Posts RSS Feed - Now At Level 6
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

Online Discussion: Tracking new emerging diseases and the next pandemic

Now At Level 6

 Post Reply Post Reply Page  <1 2526272829 30>
Author
Message
Mary008 View Drop Down
V.I.P. Member
V.I.P. Member
Avatar

Joined: June 22 2009
Status: Offline
Points: 5769
Post Options Post Options   Thanks (0) Thanks(0)   Quote Mary008 Quote  Post ReplyReply Direct Link To This Post Posted: December 20 2009 at 5:15pm
.
 
 
How Does It Work?
.................................
 
 
 
 
More on Olive Leaf extract-
 
oleuropein
....................
 

From-    nutritionplainandsimple.com
 

...there is no Calcium elenolate or Elenolic acid, ( in olive leaf extract ) but what you do find is    oleuropein.

3) Two enzymes in your blood do the job of converting oleuropein naturally. The enzymes, esterase and beta-glucosidase automatically breakdown oleuropein in the blood stream to predominately (+) dextrorotatory elenolic acid, no other process is needed. (h) (f) (d)As mentioned before elenolic acid does have stereochemistry and the dextrorotatory molecule of elenolic acid does not blood serum protein bind, remaining virucidal. That's the secret of why it works. This means that olive leaf oil extract will work in your body according to the percentage of oleuropein that's in it.
 
 
 
 
...................................
 
 
Mary008
Back to Top
Mary008 View Drop Down
V.I.P. Member
V.I.P. Member
Avatar

Joined: June 22 2009
Status: Offline
Points: 5769
Post Options Post Options   Thanks (0) Thanks(0)   Quote Mary008 Quote  Post ReplyReply Direct Link To This Post Posted: December 22 2009 at 5:55pm
.
 
 
 
 
More-
 
Nasal swine flu vaccine recalled ...

By Matthew Perrone and Marilynn Marchione,
Associated Press Writers ,
 
On Tuesday December 22, 2009, 7:14 pm EST

WASHINGTON (AP) -- Drugmaker MedImmune is recalling nearly 5 million doses of swine flu
 
vaccine because the nasal spray appears to lose strength over time, federal health officials
 
announced Tuesday.

Article here-
 
 

European News...

BBC
................
 
 
Healthy children will no longer be given a second dose of the swine flu vaccine, after the NI Department of Health revised its policy.

excerpt-
...It is understood there has been a higher rate of fever in young children following a second injection.
 
 

 (In case there is anymore Swine Flu Hiding In the Wings )

One More Time...

Old news but true..
November 20, 2009
 
You Don't need to have a fever to be     very ill with swine flu...
 
...This week, physicians in Queensland, Australia, wrote that 36 of the 106 patients admitted to Gold Coast Hospital with confirmed H1N1 infections actually had no fever.

(CDC's Error ?)
..........................
 
...But that warning isn't reflected in most of the agency's practical guidance, including when to keep children home from school or when parents should stay home from work or avoid public crowds. In those cases, flu is defined -- in part -- by having an elevated temperature.
Excerpts From-
 
 
Can your doctor spot H1N1?
..............................................
 
By Caleb Hellerman, CNN Medical News Senior Producer
November 20, 2009 1:26 p.m. EST

 
 
(it's     rare   but-)
 
If Your child looks ill and vomits/diarrhea ...don't wait another day... take the child to the doctor.
 
 
 
 
..............
 
Mary008
Back to Top
Mary008 View Drop Down
V.I.P. Member
V.I.P. Member
Avatar

Joined: June 22 2009
Status: Offline
Points: 5769
Post Options Post Options   Thanks (0) Thanks(0)   Quote Mary008 Quote  Post ReplyReply Direct Link To This Post Posted: December 23 2009 at 11:50am
.
 
 
 

Do Not Hate The New Pharmo/ Vacc Bubble...    (Invest )
..........................................................................................................................
 
Listen Public.. You really, really, really, really, need us :)
 
 
Health and Humane Services               
...................................................
 

"Today, we face a wider range of public health threats than ever before in our
history," Sebelius said.
 
"It could be anthrax delivered in an envelope.
 
It could be a dirty bomb set off in a subway car.
 
It could be a new strain of flu that our bodies have no immunity to."
 
From-
U.S. health-threat response to be reviewed
TECHNOLOGY OUTDATED
Efforts to develop new defenses are at issue

 
Novartis received a $400 million federal grant to open its new factory, which is making flu vaccine using cells instead of eggs. (Jim R. Bounds - Bloomberg)
 
By Rob Stein
Washington Post Staff Writer
Wednesday, December 2, 2009
 

Info on -
 

Which body site is suitable for genetic vaccination?
 

New Oral Mucosal DNA Vaccine
.......................................................

..............................................................
..........................................................................
 
linkinghub.elsevier.com/retrieve/pii/S0923181103000276
 
 
 
 
 

Abstract
 
Background: Direct immunization via epithelial surfaces has been considered for
many vaccine approaches, including DNA vaccines.
 
It remains to be determined,
however,
 
which body site is suitable for genetic vaccination.
 
 
Objective:
 
To characterize the effects of
 
the oral mucosa-mediated genetic vaccination,

we compared antigen-specific immune responses of the oral mucosal DNA vaccine to the
 
flank skin vaccination against influenza virus and malaria parasite.

Methods:
 
DNA vaccines against the influenza A/WSN/33 (H1N1) hemagglutinin and the malaria
 
Plasmodium berghei circumsporozoite protein were administered respectively three times
 
at 3-week intervals

into the oral mucosa, skin, or liver of hamsters.
 
The effects of their vaccine were evaluated by antigen-specific antibody production and
 
cell-mediated killing activity.

Furthermore, the in vivo malaria challenge test was also performed after the vaccination.
 
Results:
 
Significant specific antibody production was not observed in each case,
 
but interferon-gamma production and cell-mediated killing activity were strongly
induced in splenic lymphocytes from hamsters with the oral vaccination.

The in vivo malaria challenge after the oral mucosal vaccination significantly delayed
the blood-appearance day of the parasites in comparison with other immunization sites
 
(P<0.05).
 
Conclusion:
 
These results suggest that gene immunization
 
via the oral mucosa may induce cell-mediated immunity
 
more efficiently than via the skin or liver,
 
and that the oral mucosa may be one of the most suitable tissues
 
for gene gun-based DNA vaccination against infectious diseases.
 
 
 
 

What's with the $ Fear Mongering $ ?
.................................................................

Lions and Tigers and Bears Oh My!
 
 
 
..."We don't know what's coming --
 
the next public health emergency we face could be much worse."
 
... all the public health threats we face today," Sebelius said.
 
 
Interesting-
 
Egg-based technology now has "gaps" at every stage in the process?
So we are trading it for Caterpillar cells...  
       :O         (is this the company they pulled vaccine from due to facial swelling?)
 
 

...The goal, Sebelius said, will be streamlined regulations that will speed the approval of
 
new technologies that are promoted through government contracts with private
 
companies.
 

(ok... as long as the public at large is not the testing ground for the
 
new technologies that are promoted through government contracts  :/     
 
Streamlined Regulations is the GOAL...   Not Safety?  )
 
excerpts- From-
 
Health officials to review disaster plan
.................................................................
Maggie Fox, Health and Science Editor
WASHINGTON
 
 
...................
 
 
 
Mary008
 
Back to Top
Mary008 View Drop Down
V.I.P. Member
V.I.P. Member
Avatar

Joined: June 22 2009
Status: Offline
Points: 5769
Post Options Post Options   Thanks (0) Thanks(0)   Quote Mary008 Quote  Post ReplyReply Direct Link To This Post Posted: December 27 2009 at 12:01pm
.
 
 
 
 
Extensively Drug-Resistant Tuberculosis
 
(XDR) TB
................

 
 
 
Clin Infect Dis. 2008 Aug 15;47(4):450-7.
..........................................................................
 
Extensively drug-resistant tuberculosis in california, 1993-2006.
 

Banerjee R, Allen J, Westenhouse J, Oh P, Elms W, Desmond E, Nitta A, Royce S, Flood J.
Department of Pediatrics, Division of Infectious Disease, University of California, San Francisco, California, USA.
BACKGROUND:
 
Extensively drug-resistant (XDR) tuberculosis (TB)

is a global public health emergency.

 
We investigated the characteristics and extent of XDR TB
...............................................................................................

in California
.....................
......................

to inform public health interventions.

METHODS:
 
XDR TB was defined as TB
 
with resistance to at least
 
isoniazid,
 
rifampin, a fluoroquinolone, and
 
1 of 3 injectable second-line drugs
 
(amikacin, kanamycin, or capreomycin).

Pre-XDR TB was defined as TB with resistance to
 
isoniazid and rifampin and either a fluoroquinolone or
 
second-line injectable agent but not both.
 
We analyzed TB case reports submitted to the state TB registry
 
for the period 1993-2006.
 
Local health departments and the state TB laboratory were queried to ensure complete
 
drug susceptibility reporting.
 

RESULTS:
 
Among 424 multidrug-resistant (MDR) TB cases

with complete drug susceptibility reporting,
 
18
 
(4.2%) were extensively drug resistant, and
 
77
 
(18%) were pre-extensively drug resistant.

The proportion of pre-XDR TB cases increased over time,
 
from 7% in 1993 to
 
32% in 2005 (P = .02)).
 

Among XDR TB cases, 83% of cases

involved foreign-born patients,

and 43% were diagnosed in patients
 
within 6 months after arrival in the
 
United States.

Mexico was the most common country of origin.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
 
 
Five cases (29%) of XDR TB were acquired during therapy in California.

All patients with XDR TB had pulmonary disease, and most had prolonged infectious
 
periods; the median time for conversion of sputum culture results was 195 days.
 
Among 17 patients with known outcomes, 7 (41.2%) completed therapy, 5 (29.4%)
 
 moved, and 5 (29.4%) died. One patient continues to receive treatment.

 
CONCLUSIONS:
 
XDR TB and pre-XDR TB cases comprise a substantial fraction of MDR TB cases in
 
 California, indicating the need for interventions that improve surveillance, directly
 
observed therapy, and rapid drug susceptibility testing and reporting.
 
PMID: 18616396 [PubMed - indexed for MEDLINE]
 
 
 
 
Thoughts on the TB Pandemic
........................................................
 

Let's get A Clue Here...    :)

US $ 47 Billion?    And who thinks We Aren't doing enough?

any of these people?
 
..................................
 
 
 

Tuberculosis (TB) kills close to 2 million people every year
 
Highest MDR-TB incidences are in countries of the former Soviet Union

China and India account for half the world's MDR-TB cases
 
and

Tuberculosis (TB) is the leading cause of death in South Africa,57

Statistics South Africa (2008, October), ‘Mortality and causes of death in
 
South Africa, 2006: Findings from death notification’
 
 
 
 
 
 
 
.............................................................................................................
 
 
 

The funding gap is the difference between total needs for full
 
implementation of the Global Plan to Stop TB 2006-2015 and projections

of the funding that will be available over the next 10 years.
 
The total cost of the Global Plan is US$56.1 billion over ten years. This
 
includes US$9 billion for new tools working groups and US$47 billion for
 
implementation working groups.
 
 
Today, only about 45% of the total cost or an estimated US $25.3 billion
 
is likely to be available. The estimated funding gap is US $30.8 billion.
 
.................................................................................................................
 
 
TB   ( It's a Pandemic ) 

Are you asking yourself why we didn't put some of that 6 Billion Flu$
 
into this Pandemic?
 

Nearly 500,000 of the 9.2 million new cases of TB every year are
 
multidrug-resistant
 
Tuberculosis (TB) kills close to 2 million people every year
 
Highest MDR-TB incidences are in countries of the former Soviet Union

China and India account for half the world's MDR-TB cases

TB and MDR-TB are curable
 
A single person infected with MDR-TB may unknowingly infect, on
 
average, up to 15 other people

( and those 15 infect how many? )

More than 2 billion people, equal to one-third of the world's population,
 
are infected with TB bacilli, the microbes that cause TB

12 million people worldwide

source-
THE LILLY MDR-TB PARTNERSHIP
.................................................................................................................
 
 
 
 
 
TB Pandemic
........................
........................

 
 
 

March 24th 2010
is this year's
World TB Day
.........................
.................................
..........................................
 
 

...provides an opportunity for TB programs, nongovernmental
organizations, and other partners to describe problems and solutions
related to the TB pandemic and to support worldwide TB control efforts.
The U.S. theme for this year's observance is Partnerships for TB
Elimination.
 
 
 
 

Expert Rev Anti Infect Ther. 2008 Oct;6(5):713-24.
 
Extensively drug-resistant tuberculosis: new strains, new challenges.
Banerjee R, Schecter GF, Flood J, Porco TC.
Division of Infectious Disease, Department of Pediatrics, University of California San Francisco, San Francisco, CA 94143-0136, USA. banerjeer@peds.ucsf.edu
Extensively drug-resistant (XDR)-TB, defined as TB with resistance to at least isoniazid, rifampin, a fluoroquinolone and either amikacin, kanamycin or capreomycin, is a stark setback for global TB control.

Overburdened public-health systems with inadequate resources for case detection and management and high HIV coinfection rates in many regions have contributed to the emergence of XDR-TB.
 
Patients with XDR-TB have poor outcomes, prolonged infectious periods
and limited treatment options.

 
 
To prevent an epidemic of untreatable XDR-TB, improvements in XDR-TB surveillance, increased laboratory capacity for rapid detection of drug-resistant strains, better infection control and the development of new therapeutics are urgently needed.
PMID: 18847407 [PubMed - indexed for MEDLINE]
 

/pubmed/18847407?
ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_SingleItemSupl.Pubmed_Discovery_RA&linkpos=3&log$=relatedreviews&logdbfrom=pubmed
 
 
 
JAMA. 2008 Nov 12;300(18):2153-60.
 
 
Extensively drug-resistant tuberculosis in the United States, 1993-2007.
Shah NS, Pratt R, Armstrong L, Robison V, Castro KG, Cegielski JP.
 
 
 
Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, 1600 Clifton Rd, Mailstop E-10, Atlanta, GA 30333, USA.
 
 
CONTEXT:
 
Worldwide emergence of extensively drug-resistant tuberculosis (XDR-TB) has raised global public health concern,

given the limited therapy options and high mortality.

 
OBJECTIVES:
 
To describe the epidemiology of XDR-TB in the United States and to identify unique characteristics of XDR-TB cases compared with multidrug-resistant TB (MDR-TB) and drug-susceptible TB cases.
 
 
DESIGN, SETTING, AND PATIENTS:
 
Descriptive analysis of US TB cases reported from 1993 to 2007. Extensively drug-resistant TB was defined as resistance to isoniazid, a rifamycin, a fluoroquinolone, and at least 1 of amikacin, kanamycin, or capreomycin based on drug susceptibility test results from initial and follow-up specimens.
 
 
MAIN OUTCOME MEASURES:

Extensively drug-resistant TB case counts and trends, risk factors for XDR-TB, and overall survival.
 
RESULTS:

A total of 83 cases of XDR-TB were reported in the United States from 1993 to 2007. The number of XDR-TB cases declined from 18 (0.07% of 25 107 TB cases) in 1993 to 2 (0.02% of 13 293 TB cases) in 2007, reported to date. Among those with known human immunodeficiency virus (HIV) test results, 31 (53%) were HIV-positive.
 
Compared with MDR-TB cases, XDR-TB cases were more likely to have disseminated TB disease (prevalence ratio [PR], 2.06; 95% confidence interval [CI], 1.19-3.58), less likely to convert to a negative sputum culture (PR, 0.55; 95% CI, 0.33-0.94), and had a prolonged infectious period (median time to culture conversion, 183 days vs 93 days for MDR-TB; P < .001).

Twenty-six XDR-TB cases (35%) died during treatment, of whom 21 (81%) were known to be HIV-infected.
 
Mortality was higher among XDR-TB cases than among MDR-TB cases (PR, 1.82; 95% CI, 1.10-3.02) and drug-susceptible TB cases (PR, 6.10; 95% CI, 3.65-10.20).
CONCLUSION: Although the number of US XDR-TB cases has declined since 1993, coinciding with improved TB and HIV/AIDS control, cases continue to be reported each year.
 
PMID: 19001626 [PubMed - indexed for MEDLINE]
 
 
..........................
 
 
Mary008
 
Back to Top
Mary008 View Drop Down
V.I.P. Member
V.I.P. Member
Avatar

Joined: June 22 2009
Status: Offline
Points: 5769
Post Options Post Options   Thanks (0) Thanks(0)   Quote Mary008 Quote  Post ReplyReply Direct Link To This Post Posted: December 29 2009 at 6:15pm
.
 
 
 
 
 
 
 
The prevalence of tuberculosis caused by M. bovis in developing countries ... cervical lymph node tuberculosis, was established mid-19th century when more ...
www.hpa.org.uk/HPA/Topics/InfectiousDiseases/.../1204619502284/ - Cached
  • Spoligotype Diversity of Mycobacterium bovis Strains Isolated in ...

    ... bovis BCG, which was isolated in France at the end of the 19th century. ... Human-to-Human Transmission of Tuberculosis Caused by Mycobacterium bovis in ...
    jcm.asm.org/cgi/content/abstract/39/10/3623?...10...
  • ARS | Publication request: Mycobacterium bovis Shuttles between ...

    by M Palmer - 2008 - Cited by 1 - Related articles - All 7 versions
    Today, reservoirs of Mycobacterium bovis, the causative agent of ... first taken to New Zealand in the mid-19th century now occupy over 90% of New Zealand¿s ...
    www.ars.usda.gov/research/publications/publications.htm?seq... - Cached
  • What's in a name …. TB or not TB? - Elsevier

    by MD Iseman - 1996
    In the manuscript the authors refer to 'tuberculosis' caused by M. bovis. ... was apparently used first by Schoenlein in the early 19th century, ...
    linkinghub.elsevier.com/retrieve/pii/S0962847996900210
  • [The genotype of the principal Mycobacterium bovis in Argentina is ...

    by AA Cataldi - Cited by 2 - Related articles
    [The genotype of the principal Mycobacterium bovis in Argentina is also that of the ... History, 19th Century; Male; Mycobacterium bovis/classification* ...
    www.ncbi.nlm.nih.gov/pubmed/11942078
  • Livestock Disease Eradication: Evaluation of the Cooperative State ...

    In the 19th century the majority of childhood tuberculosis was of this type; ... Mycobacterium bovis in Cattle The disease caused by M. bovis in cattle is ...
    www.nap.edu/openbook.php?record_id=9144&page=7 - Cached
  • [PDF]

    Microsoft PowerPoint - Mycobacterium bovis infection ...

    File Format: PDF/Adobe Acrobat - View as HTML
    D Early in 19th century cow milk consumption linked to scrofula ..... Human Tuberculosis Caused by. Mycobacterium bovis-New York City, 2001-2004. MMWR. ...
    owendidactic.org/Mycobacterium%20bovis%20Park.pdf - Similar
  • Diseases Caused By Mycobacterium Tuberculosis - a comprehensive ...

    Human Tuberculosis Caused by Mycobacterium bovis --- New York City . .... the late 19th century, Koch's arduous work led to the discovery of Mycobacterium ...
    stanford.wellsphere.com/.../diseases-caused-by-mycobacterium-tuberculosis - Cached

  •  
     
     
     
     
     
    ...he was able to discover the bacterium causing tuberculosis (Mycobacterium tuberculosis) in 1882 (he announced the discovery on 24 March).
     
    Tuberculosis was the cause of one in seven deaths in the mid-19th century.
     
     
     
     
    Mycobacterium bovis
     
     ......................................................
     
     
     
     
     

    Why did they put Cows Blood in The Measels Vaccine?
    ..............................................................................................
    ...............................................................................................
     
     
     
    Here-
    BiologicsBloodVaccines
     
    The growth medium for measles and mumps is Medium 199 (a buffered salt solution containing vitamins and amino acids and supplemented with fetal bovine serum) containing SPGA (sucrose, phosphate, glutamate, and recombinant human albumin) as stabilizer and neomycin.

    The growth medium for rubella is Minimum Essential Medium (MEM) [a buffered salt solution containing vitamins and amino acids and supplemented with fetal bovine serum] containing recombinant human albumin and neomycin. Sorbitol and hydrolyzed gelatin stabilizer are added to the individual virus harvests.

    The cells, virus pools, and fetal bovine serum are all screened for the absence of adventitious agents.
     
     
    23789.pdf
     
     
     
     
     
    (Many novel vaccines are produced in animal cell substrates, and

    emerging infectious diseases may theoretically be transmitted from

    animals to humans through these vaccines.
     
     
     
     
     

    The reconstituted vaccine is for subcutaneous administration.

    Each 0.5 mL dose contains not less than 1,000 TCID50 (tissue culture infectious doses) of measles virus; 12,500 TCID50 of mumps virus; and 1,000 TCID50 of rubella virus. Each dose of the vaccine is calculated to contain sorbitol (14.5 mg), sodium phosphate, sucrose (1.9 mg), sodium chloride, hydrolyzed gelatin (14.5 mg), recombinant human albumin (≤0.3 mg),
    fetal bovine serum (<1 ppm), other buffer and media ingredients and approximately 25 mcg of neomycin. The product contains no preservative.

    Before reconstitution, the lyophilized vaccine is a light yellow compact crystalline plug. M-M-R II, when reconstituted as directed, is clear yellow.
    23789.pdf
     
     

    Hopefully there is no worry about..  
    ..............................................................
     

    Mycobacterium bovis is a slow-growing (16 to 20 hour generation time),
    aerobic bacterium and the causative agent of tuberculosis in cattle
    (known as bovine TB). Related to M. tuberculosis the bacteria which
    causes tuberculosis in humans M. bovis can also jump the species
    barrier and cause tuberculosis in humans.[1]
     
     
     
     
     
    Don't worry... they are discovering...   "therapeutic applications"
    ..............................................................................................................
     

    ..... finding increasing therapeutic applications. In the treatment of
     
    chronic granulomatous disease [6–9], and in severe malignant

    osteopetrosis [10,11], rhIFN-γ has clinically accepted beneficial

    effectiveness. Additionally, in the almost uniformly fatal progressive

    fibrosing lung disease, idiopathic pulmonary fibrosis
     
     
     
     
     
     
     
    And You Thought it was Just a Cough or something?
    ..............................................................................

    ..............................................................................
     
     
    Skeletal Tuberculosis:
    ........................................

    Tuberculous osteomyelitis involves mainly the thoracic and lumbar vertebrae (known as Pott's disease) followed by knee and hip. There is extensive necrosis and bony destruction with compressed fractures (with kyphosis) and extension to soft tissues, including psoas "cold" abscess.
     
     
     
     
     
    Genital Tract Tuberculosis:
    ..............................................

    .Tuberculous salpingitis and endometritis result from dissemination of tuberculosis to the fallopian tube that leads to granulomatous salpingitis, which can drain into the endometrial cavity and cause a granulomatous endometritis with irregular menstrual bleeding and infertility. In the male, tuberculosis involves prostate and epididymis most often with non-tender induration and infertility.
     
     
     
     
    Urinary Tract Tuberculosis:
    ..............................................
     
    A "sterile pyuria" with WBC's present in urine but a negative routine bacterial culture may suggest the diagnosis of renal tuberculosis. Progressive destruction of renal parenchyma occurs if not treated. Drainage to the ureters can lead to inflammation with ureteral stricture.
     
     
     
    CNS Tuberculosis:
    .................................
     
    A meningeal pattern of spread can occur, and the cerebrospinal fluid typically shows a high protein, low glucose, and lymphocytosis. The base of the brain is often involved, so that various cranial nerve signs may be present. Rarely, a solitary granuloma, or "tuberculoma", may form and manifest with seizures.
     
     
     
     
    Gastrointestinal Tuberculosis:
    ....................................................
     
    This is uncommon today because routine pasteurization of milk has eliminated Mycobacterium bovis infections. However, M. tuberculosis organisms coughed up in sputum may be swallowed into the GI tract. The classic lesions are circumferential ulcerations with stricture of the small intestine. There is a predilection for ileocecal involvement because of the abundant lymphoid tissue and slower rate of passage of lumenal contents.
     
     
     
    Adrenal Tuberculosis:
    ......................................
     
    Spread of tuberculosis to adrenals is usually bilateral, so that both adrenals are markedly enlarged. Destruction of cortex leads to Addison's disease.
     
     
     
    Scrofula:
    ................
     
    Tuberculous lymphadenitis of the cervical nodes may produce a mass of firm, matted nodes just under the mandible. There can be chronic draining fistulous tracts to overlying skin. This complication may appear in children, and Mycobacterium scrofulaceum may be cultured.
     
     
     
    Cardiac Tuberculosis:
    ...................................
     
    The pericardium is the usual site for tuberculous infection of heart. The result is a granulomatous pericarditis that can be hemorrhagic. If extensive and chronic, there can be fibrosis with calcification, leading to a constrictive pericarditis.
     

    Patterns of Infection
    ....................................

    There are two major patterns of disease with TB:
    Primary tuberculosis: seen as an initial infection, usually in children. The initial focus of infection is a small subpleural granuloma accompanied by granulomatous hilar lymph node infection.

    Together, these make up the Ghon complex. In nearly all cases, these granulomas resolve and there is no further spread of the infection.
    Secondary tuberculosis: seen mostly in adults as a reactivation of previous infection (or reinfection), particularly when health status declines. The granulomatous inflammation is much more florid and widespread.

    Typically, the upper lung lobes are most affected, and cavitation can occur.

    When resistance to infection is particularly poor, a "miliary" pattern of spread can occur in which there are a myriad of small millet seed (1-3 mm) sized granulomas, either in lung or in other organs.

    ...........................................
     
     
    Bovine Tuberculosis
    Last Updated: October 15, 2007
     

    Etiology
    .................

    Bovine tuberculosis results from infection by Mycobacterium bovis, a Gram posi-tive, acid-fast bacterium in the Mycobacterium tuberculosis complex of the family Mycobacteriaceae.
     

    Species Affected
    ...............................
     
    Cattle are the primary hosts for M. bovis, but other domesticated and wild mammals can also be infected.
    Known maintenance hosts include brush–tailed opossums (and possibly ferrets) in New Zealand, badgers in the United Kingdom and Ireland, bison and elk in Canada, and kudu and African buffalo in southern Africa.
     

    White-tailed deer in the United States (Michigan) have been classified as maintenance hosts; however, some authors now believe they may be spillover hosts.

    Species reported to be spillover hosts include sheep, goats, horses, pigs, dogs, cats, ferrets, camels, llamas, many species of wild ruminants including deer and elk; elephants, rhinoceroses, foxes, coyotes, mink, primates, opossums, otters, seals, sea lions, hares, raccoons, bears, warthogs, large cats (including lions, tigers, leopards, cheetahs and lynx) and several species of rodents.

    Most mammals may be susceptible.
     
    (Parents what do you think of Petting Zoos? )
     

    ......................................................
     
     
     
    TuberculosisThere are two major patterns of disease with TB: ... Microscopically, the inflammation produced with TB infection is granulomatous, with epithelioid ...
    library.med.utah.edu/WebPath/TUTORIAL/MTB/MTB.html - Cached - Similar
    TUBERCULOSIS IS A GRANULOMATOUS DISEASE that results from an ...by T IS - Related articles
    Tuberculosis. NEWTON G. OSBORNE, M.D., Ph.D. TUBERCULOSIS IS A GRANULOMATOUS DISEASE that results from an infection with a species of mycobac- ...
    www.liebertonline.com/doi/abs/10.1089/10424060152474703
    [PDF] Differential Diagnoses in Pulmonary DiseaseFile Format: PDF/Adobe Acrobat - Quick View
    Interstitial Pneumonia. 3. Granulomatous disease. 4. Neoplastic disease ... TB granuloma. 5. Bronchial adenoma. 6. Solitary met. 7. Round pneumonia ...
    www.learningradiology.com/lectures/.../ddxsinchesttextpdf.pdf - Similar
     
     
     
     
    .......................
     
     
    Mary008
     
    Back to Top
    Mary008 View Drop Down
    V.I.P. Member
    V.I.P. Member
    Avatar

    Joined: June 22 2009
    Status: Offline
    Points: 5769
    Post Options Post Options   Thanks (0) Thanks(0)   Quote Mary008 Quote  Post ReplyReply Direct Link To This Post Posted: December 31 2009 at 9:01am
    .
     
     
    one more swine flu update... there is very little swine flu in the USA now...
     
     
    Week 50
    ...................
     
     
    By region
     
     
    Very little flu... can't picture it's return in a big way in January...
     
     
    Back to Top
    Mary008 View Drop Down
    V.I.P. Member
    V.I.P. Member
    Avatar

    Joined: June 22 2009
    Status: Offline
    Points: 5769
    Post Options Post Options   Thanks (0) Thanks(0)   Quote Mary008 Quote  Post ReplyReply Direct Link To This Post Posted: December 31 2009 at 9:54pm
    .
     
    source
     

    News

    09 Dec 2009

     

    Tamiflu proves no defence against swine flu virus

    Treating suspected cases of swine flu with tamiflu in patients who are otherwise healthy provides no real benefit, according to researchers at the University of Birmingham.

    In research published on bmj.com, Professor Nick Freemantle and Dr Melanie Calvert found that oseltamivir, or tamiflu, the drug used to treat the H1N1 stain of the flu virus, does not necessarily prevent complications of the virus in otherwise healthy patients. It may, they conclude, have a very modest effect on reducing symptoms, but that benefit is small and the side effects and safety of the drug should be considered.

    The team examined the results of observational studies, studies conducted in real world health care settings and data from the pharmaceutical company Roche who manufacture the drug. They found that the effects of using tamiflu to teat influenza in otherwise healthy adults were clinically unimportant.

    Professor Freemantle said: “The studies focussed on those patients that had no underlying health conditions and who were otherwise healthy and who had received early treatment of antivirals. Our analysis suggests that you have to treat between 100 and 1000 patients in optimum conditions to prevent one person from developing pneumonia.”

    The threat of a widespread global pandemic of the H1N1 strain of influenza began in April 2009. Since then the British government has stockpiled supplies of oseltamivir in preparation for a further significant outbreak of the virus this winter, and patients displaying symptoms have been prescribed the drug since the initial outbreak.

    However, Professor Freemantle says: “There is very little evidence to support the widespread use of oseltamivir in the otherwise healthy population who are developing signs of influenza like illness. We have remarkably few resources in this country to spend on pharmaceuticals on health and it’s surprising to see such widespread use of oseltamivir.”

    “However the government has gone out and bought a lot of doses of the drug and I suppose the situation is like that of gun control in the US. If you’ve got a gun in the house it’s much easier to use it. But it does not mean it’s the right thing to do.”

    Professor Freemantle and Dr Calvert’s review is published in the BMJ.

    Ends

    Notes to Editors

    ..................................
     
     
    Mary008
    Back to Top
    Mary008 View Drop Down
    V.I.P. Member
    V.I.P. Member
    Avatar

    Joined: June 22 2009
    Status: Offline
    Points: 5769
    Post Options Post Options   Thanks (0) Thanks(0)   Quote Mary008 Quote  Post ReplyReply Direct Link To This Post Posted: December 31 2009 at 10:03pm
    .
     
     
    very low  "flu like" Illness in New England and Seattle...
     
     
    Check your State>>
     
     
    Sentinel%20Region%20Column%20Chart
     
     
     
     
     a bit Higher in Region 9     for "Flu Like " Illness...
    .........................................................................................
     
    Sentinel%20Region%20Column%20Chart
     
    Back to Top
    Mary008 View Drop Down
    V.I.P. Member
    V.I.P. Member
    Avatar

    Joined: June 22 2009
    Status: Offline
    Points: 5769
    Post Options Post Options   Thanks (0) Thanks(0)   Quote Mary008 Quote  Post ReplyReply Direct Link To This Post Posted: January 12 2010 at 1:47pm
    .
     
     
    Still Talking about it...
     
    Insect Cells Provide the Key to Alternative Swine Flu Vaccination
    ............................................................................................

    ScienceDaily (Jan. 12, 2010) - Scientists in Vienna have developed a new technique for producing vaccines for H1N1 -- so-called swine flu -- based on insect cells. The research, published in the Biotechnology Journal, reveals how influenza vaccines can be produced faster than through the traditional method of egg-based production, revealing a new strategy for the fight against influenza pandemics.
     
     
    ................
     
     
    Mary008
     
    Back to Top
    Mary008 View Drop Down
    V.I.P. Member
    V.I.P. Member
    Avatar

    Joined: June 22 2009
    Status: Offline
    Points: 5769
    Post Options Post Options   Thanks (0) Thanks(0)   Quote Mary008 Quote  Post ReplyReply Direct Link To This Post Posted: January 12 2010 at 1:57pm
     
     
     
     
     
    When we discussed it here...   it wasn't on the Mainstream News... Now it seems all the rage?
     
     
     
     
     
    Insect Cells Instead of Eggs for Swine Flu Vaccine?

    Novel method is faster and avoids allergy issues, researchers say
     
     
    Executive Health

    January 06, 2010, 09:00

     
     
     
     
     
     
    1. Insect cells provide the key to alternative swine flu vaccination ...

      Jan 4, 2010 ... Insect cells provide the key to alternative swine flu vaccination. Published: Monday, January 4, 2010 - 19:22 in Health & Medicine ...
      esciencenews.com/.../2010/.../insect.cells.provide.key.alternative.swine.flu.vaccination - Cached
    2. Insect Cells Provide The Key To Alternative Swine Flu Vaccination ...

      Insect Cells Provide The Key To Alternative Swine Flu Vaccination. Posted on: Tuesday, 5 January 2010, 14:10 CST. New production method can meet the demand ...
      www.redorbit.com/news/health/.../insect_cells.../index.html - Cached
    3. Insect Cells provide the Key to Alternative Swine Flu Vaccination

      Insect Cells provide the Key to Alternative Swine Flu Vaccination. 04 January 2010 Wiley - Blackwell. Under embargo until 05 January 2010 00:01 GMT ...
      www.alphagalileo.org/ViewItem.aspx?ItemId=65324...en - Cached
    4. Alternative Swine Flu Vaccination Provided By Insect Cells | Chen ...

      Alternative Swine Flu Vaccination Provided By Insect Cells ... January 9th 2010. Guwahati: A bird flu scare has hit the Kaziranga National Park in Assam ...
      www.dowell-netherlands.com/2010/.../alternative-swine-flu-vaccination.html - Cached
    5. Scientists use insect cells technology for producing swine flue ...

      Jan 5, 2010 ... The team's new method turns to insect cell based technology to create ... 2000-2010 AndhraNews.net. All Rights Reserved and are of their ...
      www.andhranews.net/.../2010/January/5-Scientists-insect-cells-48772.asp - Cached
    6. Insect Cells Provide the Key to Alternative Swine Flu Vaccination

      Jan 12, 2010 ... January 12th, 2010 at 10:12 am ... Using insect cells also bypasses the disadvantages of egg-based production, such as limited production ...
      www.impactlab.com/2010/.../insect-cells-provide-the-key-to-alternative-swine-flu-vaccination/ - 5 hours ago
    7. AllRefer Health - Insect Cells Instead of Eggs for Swine Flu Vaccine?

      Jan 6, 2010 ... Insect Cells Instead of Eggs for Swine Flu Vaccine? Novel method is faster and avoids allergy issues, researchers say. Wed Jan 06, 2010, ...
      health.allrefer.com/.../20100106634628/insect-cells-instead-of-eggs-for-swine-flu-vaccine.html - Cached
    8. Insect Cells Instead of Eggs for Swine Flu Vaccine?: MedlinePlus

      Jan 5, 2010 ... Wednesday, January 6, 2010. HealthDay news image WEDNESDAY, Jan. 6 (HealthDay News) -- A method that uses insect cell-based technology ...
      www.nlm.nih.gov/enter/medlineplus/rss?feed...url...nlm.nih...93774...
    9. Insect cells provide the key to alternative swine flu vaccination

      January 4, 2010. Scientists in Vienna have developed a new technique for producing vaccines for H1N1, 'swine flu', based on insect cells. ...
      www.physorg.com/news181855630.html - Cached
    10. Insect cells could cut vaccine production to 10 weeks

      Jan 11, 2010 ... Using two insect cell lines, namely Sf9 and BTI-TN5B1-4, the team was able to .... 2000/2010 - Decision News Media SAS - All right reserved. ...
      www.in-pharmatechnologist.com/.../Insect-cells-could-cut-vaccine-production-to-10-weeks?... - Cached
     .........................
     
     
    Mary008
    Back to Top
    Mary008 View Drop Down
    V.I.P. Member
    V.I.P. Member
    Avatar

    Joined: June 22 2009
    Status: Offline
    Points: 5769
    Post Options Post Options   Thanks (0) Thanks(0)   Quote Mary008 Quote  Post ReplyReply Direct Link To This Post Posted: January 12 2010 at 1:58pm
    .
     
     
    If we see it often enough will we accept it?   Want to be injected with it?
     
     
     
     
    1. Researchers Produce H1N1 Vaccine With Insect Cells - Scientific ...

      Jan 5, 2010 ... Tuesday, January 5, 2010 - 15:49 in Health & Medicine. Using insect cells, scientists in Vienna have developed an alternative method for ...
      esciencenews.com/.../2010/.../researchers.produce.h1n1.vaccine.with.insect.cells - Cached
    2. Bill Perkins - Scientists Create Insect-Cell Approach to Produce ...

      Scientists Create Insect-Cell Approach to Produce Swine Flu Vaccines. Monday, 4. January 2010, 19:13:50. Austria, Vienna Institute of BioTechnology, ...
      my.opera.com/SavedNotFried/blog/show.dml/6072141 - Cached
    3. Insect cells provide alternative technique for swine flu vaccine ...

      5 January, 2010. Scientists in Vienna have developed a new technique for producing swine flu vaccines based on insect cells. The research, published in the ...
      www.manufacturingchemist.com/story.asp?storycode=56885 - Cached
    4. Scientists use insect cells technology for producing swine flue ...

      Home/ sep. background blue line, Friday 8th January, 2010. Scientists use insect cells technology for producing swine flue vaccine ...
      feeds.bignewsnetwork.com/?sid=585279 - Cached
    5. Insect Cells Instead of Eggs for Swine Flu Vaccine? - US News and ...

      Jan 6, 2010 ... Comment. Posted: January 6, 2010 ... The use of insect cells also avoids other egg-based production disadvantages, such as allergic ...
      www.usnews.com/.../2010/.../insect-cells-instead-of-eggs-for-swine-flu-vaccine.html - Cached
    6. Scientists use insect cells technology for producing swine flue ...

      Jan 5, 2010 ... Scientists use insect cells technology for producing swine flue vaccine. By ANI. January 5th, 2010. WASHINGTON - Austrian researchers have ...
      blog.taragana.com/.../2010/.../scientists-use-insect-cells-technology-for-producing-swine-flue-vaccine-2623/ - Cached
    7. Darwiniana » Insect cells and H1N1

      Jan 12, 2010 ... Insect Cells Provide the Key to Alternative Swine Flu Vaccination ScienceDaily (Jan. 12, 2010) — Scientists in Vienna have developed a new ...
      darwiniana.com/2010/01/12/insect-cells-and-h1n1/ - 4 hours ago
    8. 2010.01.06 -- Insect Cells Instead of Eggs for Swine Flu Vaccine?

      Jan 6, 2010 ... January 06, 2010 ... The use of insect cells also avoids other egg-based production disadvantages, such as allergic reactions to egg ...
      www.womenshealth.gov/news/english/634628.htm - Cached
    9. Cellometer® Automated Cell Counter Applications - Insect Cells

      Insect cells are routinely used in transfection, plaques assays, ... "Improving Cell Counting Data Quality & Throughput" on Wednesday, January 20, 2010 ...
      www.nexcelom.com/Applications/AutoT4_InsectCells.html - Cached
    10. Wiley::Insect Cells Provide the Key to Alternative Swine Flu ...

      January 05, 2010. Vienna, Austria ... Using insect cells also bypasses the disadvantages of egg-based production, such as limited production capacity, ...
      ca.wiley.com/WileyCDA/PressRelease/pressReleaseId-65677.html - Cached
    .......................
     
     
    Mary008
     
     
     
     
    Back to Top
    Mary008 View Drop Down
    V.I.P. Member
    V.I.P. Member
    Avatar

    Joined: June 22 2009
    Status: Offline
    Points: 5769
    Post Options Post Options   Thanks (0) Thanks(0)   Quote Mary008 Quote  Post ReplyReply Direct Link To This Post Posted: January 14 2010 at 12:36pm
    .
     
     
     
    FluBlok, a next generation influenza vaccine manufactured in insect cells
     
     
     
     

    Manon M.J. CoxCorresponding%20Author%20Contact%20Information, a, E-mail%20The%20Corresponding%20Author and Jason R. Hollistera

    aProtein Sciences Corporation, 1000 Research Parkway, Meriden, CT 06450, USA


    Available online 17 March 2009.

    Abstract

    FluBlok, a recombinant trivalent hemagglutinin (rHA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg-based trivalent inactivated influenza vaccine (TIV). Its manufacturing process presents the possibility for safe and expeditious vaccine production. FluBlok contains three times more HA than TIV and does not contain egg-protein or preservatives. The high purity of the antigen enables administration at higher doses without a significant increase in side-effects in human subjects.

    The insect cell–baculovirus production technology is particularly suitable for influenza where annual adjustment of the vaccine is required. The baculovirus–insect expression system is generally considered a safe production system, with limited growth potential for adventitious agents. Still regulators question and challenge the safety of this novel cell substrate as FluBlok continues to advance toward product approval. This review provides an overview of cell substrate characterization for expresSF cell line used for the manufacturing of FluBlok.

    In addition, this review includes an update on the clinical development of FluBlok. The highly purified protein vaccine, administered at three times higher antigen content than TIV, is well tolerated and results in stronger immunogenicity, a long lasting immune response and provides cross-protection against drift influenza viruses.

    Back to Top
    Mary008 View Drop Down
    V.I.P. Member
    V.I.P. Member
    Avatar

    Joined: June 22 2009
    Status: Offline
    Points: 5769
    Post Options Post Options   Thanks (0) Thanks(0)   Quote Mary008 Quote  Post ReplyReply Direct Link To This Post Posted: January 15 2010 at 5:44pm
    .
     
     
     

    Analyst: Adjuvanted H1N1 vaccines helped stir Europe's debate

    Robert Roos * News Editor

    Jan 15, 2010 (CIDRAP News)

     
     
     
    Off to a bad start

     
    "I think in Europe the entire pandemic vaccine supply situation got off to a bad start
     
    because European regulators opted for adjuvanted vaccines, which resulted in a lot of
     
    negative publicity across Europe" and reduced the public's interest in getting vaccinated,
     
    Kresse told CIDRAP News.
     
     
    article here-
     
     
     
    Back to Top
    Mary008 View Drop Down
    V.I.P. Member
    V.I.P. Member
    Avatar

    Joined: June 22 2009
    Status: Offline
    Points: 5769
    Post Options Post Options   Thanks (0) Thanks(0)   Quote Mary008 Quote  Post ReplyReply Direct Link To This Post Posted: January 16 2010 at 11:02am
    .
     
    Week One
    ....................
    .........................
    .....................................
     
     
     
    Very low level of Influenza Like Illness in The US
    ......................................................................................
     
     
    INFLUENZA%20Virus%20Isolated 
     
     
     
    Week One...
     
     
     
     
     
     
     
    Old Time Cures
    ...........................
     
     
    Dandelions, onions, thyme, rosemary, raw honey
     
     
     
     
     
    ...............
     
     
    Mary008
     
    Back to Top
    Mary008 View Drop Down
    V.I.P. Member
    V.I.P. Member
    Avatar

    Joined: June 22 2009
    Status: Offline
    Points: 5769
    Post Options Post Options   Thanks (0) Thanks(0)   Quote Mary008 Quote  Post ReplyReply Direct Link To This Post Posted: January 22 2010 at 10:12pm
    ,Author KENPEI          http://commons.wikimedia.org/wiki/File:Agrimonia_pilosa1.jpg
    File:Agrimonia%20pilosa1.jpg
     
     
     

    Agrimonia pilosa - Hairy Agrimony (eastern Europe, Asia)
    ................................................................................................
     
     
     
    Microbiol Immunol. 2010 Jan;54(1):11-9.
     
     
    Broad-spectrum antiviral effect of Agrimonia pilosa extract on influenza viruses.
    ..............................................................................................................................................
     
     
    Shin WJ, Lee KH, Park MH, Seong BL.
    Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 120-749.
     
    Influenza virus continues to emerge and re-emerge, posing new threats for humans. Here we tested various Korean medicinal plant extracts for potential antiviral activity against influenza viruses. Among them,
     
     
    an extract of Agrimonia pilosa was shown to be highly effective against all three subtypes of human influenza viruses including H1N1 and H3N2 influenza A subtypes and influenza B virus.

    The EC(50) value against influenza A virus, as tested by the plaque reduction assay on MDCK cells, was 14-23 mug/ml.

     
    The extract also exhibited a virucidal effect at a concentration of 160-570 ng/ml against influenza A and B viruses when the viruses were treated with the extract prior to plaque assay.

     
    In addition, when tested in embryonated chicken eggs the extract exhibited a strong inhibitory effect in ovo on the H9N2 avian influenza virus at a concentration of 280 ng/ml.

    Quantitative RT-PCR analysis data showed that the extract, to some degree, suppressed viral RNA synthesis in MDCK cells. HI and inhibition of neuraminidase were observed only at high concentrations of the extract. And yet, the extract's antiviral activity required direct contact between it and the virus,

     
    suggesting that its antiviral action is mediated by the viral membrane, but does not involve the two major surface antigens, HA and NA, of the virus.

     
    The broad-spectrum antiviral activity of Agrimonia pilosa extract on various subtypes of influenza viruses
     
     
    merits further investigation as it may provide a means of managing avian influenza
     
    infections in poultry farms and potential avian-human transmission.
     
     
    PMID: 20055938 [PubMed - in process]
     
     
    os
    =1
     
     
     
    .......................
     
     
    Mary008
    Back to Top
    Mary008 View Drop Down
    V.I.P. Member
    V.I.P. Member
    Avatar

    Joined: June 22 2009
    Status: Offline
    Points: 5769
    Post Options Post Options   Thanks (0) Thanks(0)   Quote Mary008 Quote  Post ReplyReply Direct Link To This Post Posted: January 23 2010 at 11:06pm
    File:Illustration%20Agrimonia%20eupatoria0.jpg
    .
     
     
    Agrimonia eupatoria
    ................................
     
     
     is a species of agrimony that is often referred to as common agrimony, church steeples or
     
    sticklewort. The whole plant is dark green with numerous soft hairs. The soft hairs aid in
     
    the plant's seed pods sticking to any animal or person coming in contact with the plant.
     
    The flower spikes have a spicy odor like apricots.
     
     
    wikipedia
     
     
     
     
    ............................................................................
     
     
     
    Phytotherapy Research
     
    Volume 19 Issue 4, Pages 355 - 358
    Published Online: 22 Jul 2005
     
     
    Research Article
     
    Inhibition of hepatitis B virus by an aqueous extract of Agrimonia eupatoria L.
     
     
    Dur Han Kwon 1 *, Hyuk Yun Kwon 2, Hyun Jung Kim 3, Eun Joo Chang 3, Man Bae Kim 4, Seung Kew Yoon 5, Eun Young Song 1, Do Young Yoon 1, Young Hee Lee 1, In Seong Choi 1, Yong Kyung Choi 1
    1Cell Biology Laboratory, Korea Research Institute of Bioscience and Biotechnology, Daejon 305-333, Republic of Korea
    2Department of Food Technology Chungnam National University, Daejon 305-764, Republic of Korea
    3Biokorea Co. Seoul, 135-280, Republic of Korea
    4Kyongnam Agricultural Research and Extension Services, Jinju 660-985, Republic of Korea
    5Collge of Medicine, The Catholic University of Korea, Seoul 137-040, Republic of Korea
    email: Dur Han Kwon (dhkwon@kribb.re.kr)

    *Correspondence to Dur Han Kwon, Cell Biology Laboratory, Korea Research Institute of Bioscience and Biotechnology, Eoundong 52, Yuseong-gu, Daejon 305-333, Republic of Korea.

    setDOI("ADOI=10.1002/ptr.1689")

    Keywords
    genus Agrimonia • antiviral activity • aqueous extracts • HBsAg • seasonal variation

    Abstract
    Inhibition of HBsAg release against hepatitis B virus (HBV) was investigated in an aqueous extract prepared from the aerial parts (stems and leaves) of Agrimonia eupatoria. The inhibitory effect on HBsAg secretion was footed using aqueous extracts of Agrimonia eupatoria at four different temperatures (37 °C 45 °C, 55 °C and 60 °C), and the extract prepared at 60 °C was found to have the greatest effect. The inhibitory activity of Agrimonia eupatoria extracts on HBsAg secretion varied over the growing season and was the highest at mid-July. This inhibitory activity was also shown with the aqueous extracts of two other species of the genus Agrimonia: A. pilosa and A. coreana pilosella. These results suggest that some plants of the genus Agrimonia contain potential antiviral activity against HBV. Copyright © 2005 John Wiley & Sons, Ltd.

    source-
     
     
     
     
     
    ............................................
     
     
     
     
     Mary008
    Back to Top
    Mary008 View Drop Down
    V.I.P. Member
    V.I.P. Member
    Avatar

    Joined: June 22 2009
    Status: Offline
    Points: 5769
    Post Options Post Options   Thanks (0) Thanks(0)   Quote Mary008 Quote  Post ReplyReply Direct Link To This Post Posted: January 24 2010 at 7:09pm
    http://en.wikipedia.org/wiki/Angelica  by TeunSpaans
     File:Gewone%20engwortel%20R0012880%20Plant.JPG
     
     
    Angelica
    .............
     
     
     
     
    EURO W.H.O.
    ......................
    ..........................
    ........................................
     
     
     
     
    Anti-Influenza Drug Discovery: Structure-Activity Relationship and Mechanistic Insight into Novel Angelicin Derivatives.

    Sat, 23 Jan 2010 20:05 GMT
     
    Anti-Influenza Drug Discovery: Structure-Activity Relationship and Mechanistic Insight into Novel Angelicin Derivatives.
     
    J Med Chem. 2010 Jan 21;
     
     
    Authors: Yeh JY, Coumar MS, Horng JT, Shiao HY, Kuo FM, Lee HL, Chen IC, Chang CW, Tang WF, Tseng SN, Chen CJ, Shih SR, Hsu JT, Liao CC, Chao YS, Hsieh HP
     
     
     
     
    By using a cell-based high throughput screening campaign, a novel angelicin derivative 6a was identified to inhibit influenza A (H1N1) virus induced cytopathic effect in Madin-Darby canine kidney cell culture in low micromolar range. Detailed structure-activity relationship studies of 6a
     
     
     revealed that the angelicin scaffold is essential for activity in pharmacophore B, while meta-substituted phenyl/2-thiophene rings are optimal in pharmacophore A and C. The optimized lead 4-methyl-9-phenyl-8-(thiophene-2-carbonyl)-furo[2,3-h]chromen-2-one (8g, IC(50) = 70 nM) showed 64-fold enhanced activity compared to the high throughput screening (HTS) hit 6a.

    Also, 8g was found effective in case of influenza A (H3N2) and influenza B virus strains

    similar to approved anti-influenza drug zanamivir (4).
     

    Preliminary mechanistic studies suggest that these compounds act as
    anti-influenza agents by inhibiting ribonucleoprotein (RNP) complex
    associated activity and have the potential to be developed further, which
    could form the basis for developing additional defense against influenza
    pandemics.
     
     
     
    PMID: 20092255 [PubMed - as supplied by publisher]
     
     
     
    .......................................
     
     
     Mary008
    Back to Top
    Mary008 View Drop Down
    V.I.P. Member
    V.I.P. Member
    Avatar

    Joined: June 22 2009
    Status: Offline
    Points: 5769
    Post Options Post Options   Thanks (0) Thanks(0)   Quote Mary008 Quote  Post ReplyReply Direct Link To This Post Posted: January 26 2010 at 9:27am
    .
     
     
     
    India questions WHO on H1N1 false pandemic reports
    .................................................................................
     
     
     
     
     

    ..................................................................................................................
     
     
     
     
     
     
    WHO to review its handling of H1N1 flu pandemic
    ..........................................................................
     
    Tue, Jan 12 2010
     * WHO denies drug companies influenced H1N1 decisions

    * WHO says its response to flu might have been better
     
     
     
    .............................
     
     
     
     
     
     
    No U.S. decision on H1N1 vaccine orders - official
    .........................................................................
     
     

    WASHINGTON (Reuters) - The United States has made no decision on whether to cancel or

    sell any of its orders for the H1N1 vaccine, unlike some European countries with a vast
     
    oversupply of shots, a federal health official said on Thursday.
     
     
     
     
    ..........
     
     
     
    Back to Top
    Mary008 View Drop Down
    V.I.P. Member
    V.I.P. Member
    Avatar

    Joined: June 22 2009
    Status: Offline
    Points: 5769
    Post Options Post Options   Thanks (0) Thanks(0)   Quote Mary008 Quote  Post ReplyReply Direct Link To This Post Posted: January 26 2010 at 9:40am
    .
     
     
     

    Public hearing on the handling of the Swine Flu pandemic

    ................................................................................................
     
     
     
     
     
    Strasbourg, 21.01.2010- A public parliamentary hearing titled "The handling of the H1N1 pandemic: more transparency needed?" is to be held on the fringe of the plenary session of the Parliamentary Assembly of the Council of Europe (PACE) in Strasbourg from 8.15-10 a.m. on Tuesday 26 January, immediately followed by a press conference.
     
     
     
    The hearing, organised by the Assembly's Committee on Social, Health and Family Affairs,
     
    will bring together representatives of the World Health Organisation (WHO) and of
     
    European vaccine manufacturers, as well as independent medical experts, to discuss this
     
    topic with parliamentarians. Some members of the Assembly- including the outgoing Chair
     
    of PACE's Sub-committee on Health Wolfgang Wodarg (Germany, SOC) - requested in a
     
    motion in December that the Assembly look into this question.

     

    The hearing is open to the press. Both hearing and press conference will be webcast live.

     
    The Assembly may also hold an urgent debate on this topic on Thursday 28 January at 10 a.m., if it decides to do so when it adopts its agenda (around midday on Monday 25 January). In this case, the Assembly would debate and vote on a draft resolution.

    Programme and list of participants (PDF)

    Biographies of participants (PDF)

    Motion by Mr Wodarg and others (PDF)

    Session announcement

    Practical arrangements

    The hearing takes place from 8.15a.m. to 10a.m. in Room 1 of the Palais de l'Europe in Strasbourg, and is open to the press.

    Media interested in attending are invited to request accreditation from Danielle Schreiber-Somoza of the Council of Europe's Communication Directorate, e-mail danielle.schreiber-somoza@coe.int, tel. +33 3 88 41 25 44.

    Video of both the hearing and the following press conference - in the original language and interpreted into English and French - will be webcast live via the following link: http://tv.coe.int/internet/press.html. Video recordings will also be available for download later.

    If an urgent debate takes place on Thursday morning, this will also be webcast live from the following link: http://tv.coe.int/internet. Additional documentation is available on the Assembly’s website http://assembly.coe.int.

    For further information, please contact Micaela Catalano, Francesc Ferrer, Angus Macdonald or Nathalie Bargellini of PACE’s Communication Division on e-mail pace.com@coe.int, tel. +33 (0)3 88 41 31 93.

    1 . Following the recent parliamentary elections in Germany, Mr Wodarg ceases to be a member of the Assembly, and Chair of its Sub-committee on Health, on Monday 25 January. He will attend the hearing in an expert capacity.

    Council of Europe Directorate of Communication
    Tel: +33 (0)3 88 41 25 60
    Fax:+33 (0)3 88 41 39 11

    pressunit@coe.int

    www.coe.int

     
    Back to Top
    Mary008 View Drop Down
    V.I.P. Member
    V.I.P. Member
    Avatar

    Joined: June 22 2009
    Status: Offline
    Points: 5769
    Post Options Post Options   Thanks (0) Thanks(0)   Quote Mary008 Quote  Post ReplyReply Direct Link To This Post Posted: January 26 2010 at 10:10am
    .
     
     
    Please Follow Up On The  (above post )  Hearing VIDEO >>>   Here...
     
     
    Back to Top
     Post Reply Post Reply Page  <1 2526272829 30>
      Share Topic   

    Forum Jump Forum Permissions View Drop Down